Drug intelligence / Profile preview

RMD1701

Development stage: Preclinical
Lead developer: Remedium Bio
Modality: Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Parenteral

Overview

RMD1701 is an investigational gene therapy candidate being developed by Remedium Bio (formerly Remedium Technologies) for the treatment and prevention of viral respiratory infections. The program is designed to function as a viral entry inhibitor, utilizing both adeno-associated virus (AAV) and lipid nanoparticle (LNP) delivery platforms to express therapeutic agents that block viruses from entering host cells. As of 2024, RMD1701 is in the IND-enabling stage of development, representing a novel approach to managing respiratory viral threats through localized or systemic gene delivery.

Beyond the preview

Go deeper on RMD1701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RMD1701.

Explore the full profile